---
title: "Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update"
nct_id: NCT04170140
overall_status: COMPLETED
sponsor: Sanofi Pasteur, a Sanofi Company
study_type: OBSERVATIONAL
primary_condition: Dengue Virus Infection
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04170140.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04170140"
ct_last_update_post_date: 2023-09-18
last_seen_at: "2026-05-12T06:02:47.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

**Official Title:** A Cross-sectional Survey to Evaluate Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

**NCT ID:** [NCT04170140](https://clinicaltrials.gov/study/NCT04170140)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 300
- **Lead Sponsor:** Sanofi Pasteur, a Sanofi Company
- **Conditions:** Dengue Virus Infection
- **Start Date:** 2020-01-07
- **Completion Date:** 2020-03-05
- **CT.gov Last Update:** 2023-09-18

## Brief Summary

The primary objective of the study is to evaluate the effectiveness of additional risk minimization measures material by assessing the knowledge and understanding of healthcare professionals regarding the key safety messages provided in the material.

The secondary objective of the study is to evaluate if healthcare professionals know Dengvaxia product information, namely, age indication and contraindications.

## Detailed Description

The study is a cross-sectional Survey. Study data are collected through a questionnaire.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion criteria:

\- Healthcare professionals who are current or past prescribers of Dengvaxia

Exclusion criteria:

* Healthcare professionals who have never prescribed Dengvaxia
* Healthcare professionals who may have a conflict of interest with the survey (i.e. Healthcare professionals employed by regulatory bodies, pharmaceutical industries)
* Healthcare professionales who have participated in testing the questionnaire for comprehensibility, consistency and the appropriateness of medical terms

The above information is not intended to contain all considerations relevant to participation in the survey.
```

## Arms

- **Prescribers of Dengvaxia** — Healthcare professionals who are current or past prescribers of Dengvaxia

## Interventions

- **No intervention** (OTHER) — Questionnaire

## Primary Outcomes

- **Healthcare professionals' knowledge and understanding of key safety messages provided in risk minimization measures materials** _(time frame: Day 0)_ — Knowledge and understanding of key safety messages are assessed through a questionnaire

## Secondary Outcomes

- **Healthcare professionals' knowledge of Dengvaxia product information** _(time frame: Day 0)_

## Locations (1)

- Real World Evidence Solutions IQVIA, La Defense, France

## Recent Field Changes (last 30 days)

- `outcomes.primary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.real world evidence solutions iqvia|la defense||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04170140.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04170140*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*